What is Brentuximab?
Brentuximab is a targeted therapy used to treat certain types of lymphoma [1]. It is an antibody-drug conjugate, meaning it combines a monoclonal antibody with a cytotoxic agent [1]. The antibody specifically targets CD30, a protein found on the surface of lymphoma cells, delivering the toxic agent directly to these cells to kill them while minimizing damage to healthy tissues [1][2].
What types of cancer does Brentuximab treat?
Brentuximab vedotin is approved for the treatment of adult patients with:
* Hodgkin lymphoma (HL) after failure of at least one prior multi-agent chemotherapy regimen [1][3].
* Relapsed or refractory classical Hodgkin lymphoma [4].
* Consolidated treatment in patients with classical Hodgkin lymphoma that is at high risk of relapse or progression following autologous stem cell transplantation (ASCT) [4].
* Relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) [1][3][4].
* Cutaneous anaplastic large cell lymphoma (cALCL) or CD30-positive mycosis fungoides (MF) in patients who have received prior systemic therapy [4].
How does Brentuximab work?
Brentuximab vedotin works by binding to the CD30 antigen on the surface of malignant cells [1]. Once bound, the drug conjugate is internalized by the cell, where the cytotoxic agent, monomethyl auristatin E (MMAE), is released [1]. MMAE disrupts the microtubule network within the cell, leading to cell cycle arrest and apoptosis (programmed cell death) [1].
When was Brentuximab approved in the UK?
Brentuximab vedotin received its initial marketing authorization in the European Union, including the UK, in October 2011 [5].
What are the patent details for Brentuximab in the UK?
Information regarding specific UK patent expiry dates for Brentuximab is not publicly available in the provided sources. Patent information for pharmaceuticals can be complex, often involving multiple patents covering different aspects of the drug, such as the active ingredient, manufacturing processes, and specific uses [6]. These patents can have varying expiry dates [6].
Who makes Brentuximab?
Brentuximab vedotin is manufactured by Seagen Inc., a biotechnology company [1][7]. Seagen was acquired by Pfizer in December 2023 [8].
What are the alternatives to Brentuximab for Hodgkin lymphoma?
For Hodgkin lymphoma, alternative treatments depend on the stage and previous therapies received. Options may include other chemotherapy regimens, radiation therapy, or stem cell transplantation [9]. For relapsed or refractory disease, treatments might involve immunotherapy or other targeted agents [4].
What are the alternatives to Brentuximab for anaplastic large cell lymphoma?
Treatment for anaplastic large cell lymphoma can include chemotherapy, radiation therapy, stem cell transplantation, or other targeted therapies depending on the specific subtype and patient factors [10].
Can biosimilars of Brentuximab be developed?
The development of biosimilars for complex biological drugs like Brentuximab is possible but challenging [11]. Biosimilars are highly similar to their reference biologic product, with no clinically meaningful differences in terms of safety, purity, and potency [11]. However, due to the complexity of manufacturing such drugs, the development and regulatory approval pathway for biosimilars can be extensive [11]. The patent landscape for Brentuximab would be a critical factor in the timeline for any potential biosimilar entry.
*
**Sources:
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris
[2] https://www.cancer.gov/about-cancer/treatment/types/lymphoma/hodgkin/brentuximab-pdq
[3] https://www.nhs.uk/medicines/brentuximab-vedotin/
[4] https://www.adc.bmj.com/content/92/6/893
[5] https://www.gov.uk/drug-safety-updates/brentuximab-vedotin-adcetris-potential-risk-of-progressive-multifocal-leukoencephalopathy-pml
[6] https://www.mondigroup.com/en/insights/blogs/2020-01-17-understanding-drug-patent-protection/
[7] https://www.seattletimes.com/business/technology/seagen-inc-a-biotech-darling-built-on-cancer-drugs-a-look-at-the-bothell-companies-growth/
[8] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen
[9] https://www.nhs.uk/conditions/hodgkins-lymphoma/treatment/
[10] https://www.lymphoma-action.org.uk/about-lymphoma/types-lymphoma/anaplastic-large-cell-lymphoma
[11] https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicinal-products